Sex and Pubertal Status Moderate the Association Between ADHD and Depression Symptoms: An Examination from Preadolescence Through Late Adolescence

Instructions

Click the red REGISTER button to pay the $10 fee and take the posttest
Click here to return to the JCP CME article.

Overview

Despite high risk for depression, not all youth with ADHD develop a mood disorder. Which children are at highest risk? How does puberty affect the risk?


Read the whole article at psychiatrist.com here:
Sex and Pubertal Status Moderate the Association Between ADHD and Depression Symptoms: An Examination from Preadolescence Through Late Adolescence

© Copyright 2019 Physicians Postgraduate Press, Inc.

Target Audience

Psychiatrists

Learning Objectives

Consider the impact of sex and pubertal status on the association between ADHD and depression symptoms in young patients

Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Activity opens: 
05/31/2019
Activity expires: 
06/30/2021
Cost:
$10.00
Rating: 
0

CME Background

Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.

CME Objective

After studying this article, you should be able to:

  • Consider the impact of sex and pubertal status on the association between ADHD and depression symptoms in young patients

Statement of Need and Purpose

Studies have documented a high rate of comorbidity between ADHD and depression in adolescents. The AAP clinical practice guidelines recommend that when evaluating a child for ADHD, the clinician should also assess for coexisting conditions such as depression. However, the overlapping features of the symptoms of ADHD and depression make it challenging for clinicians to make an accurate diagnosis, which can result in worse treatment outcomes. Clinicians need education on screening instruments covering overlapping ADHD and depression symptoms to aid in diagnosis. Clinicians also need guidance on when to refer a child with ADHD to a specialist for optimal assessment and treatment.

Release, Expiration, and Review Dates

This educational activity was published in May 2019 and is eligible for AMA PRA Category 1 Credit™ through June 30, 2021. The latest review of this material was April 2019.

Disclosure of off-label usage

The authors have determined that, to the best of their knowledge, no investigational information about pharmaceutical agents that is outside US Food and Drug Administration-approved labeling has been presented in this article.

Funding/support

Dr Babinski’s research was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under Building Interdisciplinary Research Careers in Women’s Health award number K12HD055882.

Disclaimer

This presentation reflects the views of the authors and may not reflect the opinions or views of the MTA 192 Study Investigators or the National Institutes of Health.

Additional information

Data used in the preparation of this article were obtained from the limited access datasets distributed from the National Institutes of Health-supported Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder (MTA). This is a multisite, clinical trial and long-term follow-up study of children with ADHD who were randomly assigned to one of 4 treatment modalities. The study was conducted by the MTA Cooperative Group and supported by the National Institute of Mental Health with funds also contributed by the National Institute of Drug Abuse, the Department of Justice, and the Department of Education. The MTA Study has been supported by the following grant numbers: U01MH50440, U01MH50447, U01MH50453, U01MH50454, U01MH50461, and U01MH50467 and the following contract numbers: N01MH19204, N01MH19207, N01MH19208, N01MH19209, N01MH19210, N01MH19211, N01MH19212, HHSN271920800003-C, HHSN271920800004-C, HHSN271920800005-C, HHSN271920800006-C, HHSN271920800007-C, HHSN271920800008-C, and HHSN271920800009-C. The ClinicalTrials.gov identifier is NCT00000388.

Faculty Affiliation


Dara E. Babinski, PhD*
Department of Psychiatry, Penn State College of Medicine, Hershey, Pennsylvania



Daniel A. Waschbusch, PhD
Department of Psychiatry, Penn State College of Medicine, Hershey, Pennsylvania



James G. Waxmonsky, MD
Department of Psychiatry, Penn State College of Medicine, Hershey, Pennsylvania


*Corresponding author: Dara E. Babinski, PhD, Department of Psychiatry, 22 Northeast Dr, Hershey, PA 17033 (dbabinski@pennstatehealth.psu.edu).

FINANCIAL DISCLOSURE

All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Marlene P. Freeman, MD, Editor in Chief of The Journal of Clinical Psychiatry, has received research funding from JayMac and Sage; has been a member of the advisory boards for Otsuka, Alkermes, and Sunovion; has been a member of the Independent Data Safety and Monitoring Committee for Janssen; and, as a Massachusetts General Hospital (MGH) employee, works with the MGH National Pregnancy Registry, which is sponsored by Teva, Alkermes, Otsuka, Actavis, and Sunovion, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. No member of the CME Institute staff reported any relevant personal financial relationships.

In the past 3 years, Dr Waxmonsky has received research funding from National Institutes of Health, Supernus, and Pfizer and served on the advisory boards for Noven, Ironshore, NLS Pharma, and Purdue Pharma. Dr Babinski has received research support from Purdue Pharma. Dr Waschbusch has no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Price

Cost:
$10.00
Please login or register to take this activity.

Register for free on our site to participate in this and many free CME courses. There is a $10 processing fee for this activity.